| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
11,447,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
23,616 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.000001 - $0.008 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Anthera Pharmaceuticals is a biopharmaceutical company focused on advancing the development and commercialization of medicines that benefit patients with medical needs. Co. has two compounds in development, Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy intended for the treatment of patients with Exocrine Pancreatic Insufficiency, often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Isaly Samuel D |
Director |
– • • |
2011-05-17 |
4 |
S |
$8.32 |
$832,000 |
I/I |
(100,000) |
3,208,334 |
|
- |
|
| Truex Paul F |
President and CEO |
• • – |
2011-05-16 |
4 |
AS |
$7.16 |
$107,339 |
I/I |
(15,000) |
692,003 |
|
- |
|
| Isaly Samuel D |
Director |
– • • |
2011-05-16 |
4 |
S |
$7.20 |
$86,400 |
I/I |
(12,000) |
3,308,334 |
|
- |
|
| Isaly Samuel D |
Director |
– • • |
2011-05-11 |
4 |
S |
$7.22 |
$93,860 |
I/I |
(13,000) |
3,320,334 |
|
- |
|
| Isaly Samuel D |
Director |
– • • |
2011-05-10 |
4 |
S |
$7.23 |
$769,272 |
I/I |
(106,400) |
3,333,334 |
|
- |
|
| Truex Paul F |
President and CEO |
• • – |
2011-05-09 |
4 |
GD |
$0.00 |
$0 |
I/I |
9,000 |
707,003 |
|
- |
|
| Isaly Samuel D |
Director |
– • • |
2011-05-09 |
4 |
S |
$7.26 |
$72,600 |
I/I |
(10,000) |
3,439,734 |
|
- |
|
| Salzman Alan E |
10% Owner |
– – • |
2011-05-05 |
4 |
S |
$7.01 |
$2,717,777 |
D/D |
(387,700) |
18,470 |
|
- |
|
| Salzman Alan E |
10% Owner |
– – • |
2011-05-04 |
4 |
S |
$7.00 |
$1,400,000 |
D/D |
(200,000) |
19,749 |
|
- |
|
| Truex Paul F |
President and CEO |
• • – |
2011-05-03 |
4 |
GA |
$0.00 |
$0 |
I/I |
30,000 |
716,003 |
|
- |
|
| Truex Paul F |
President and CEO |
• • – |
2011-05-03 |
4 |
GD |
$0.00 |
$0 |
D/D |
30,000 |
91,122 |
|
- |
|
| Salzman Alan E |
10% Owner |
– – • |
2011-05-03 |
4 |
S |
$7.00 |
$700,000 |
D/D |
(100,000) |
20,409 |
|
- |
|
| Truex Paul F |
President and CEO |
• • – |
2011-04-13 |
4 |
OE |
$0.26 |
$7,800 |
D/D |
30,000 |
121,122 |
|
- |
|
| Odink Debra |
VP, Pharmaceutical R&D |
• • – |
2011-04-13 |
4 |
OE |
$1.51 |
$5,000 |
D/D |
3,311 |
29,311 |
|
- |
|
| Truex Paul F |
President and CEO |
• • – |
2011-04-07 |
4 |
GD |
$0.00 |
$0 |
I/I |
7,250 |
686,003 |
|
- |
|
| Truex Paul F |
President and CEO |
• • – |
2011-03-30 |
4 |
GA |
$0.00 |
$0 |
I/I |
693,253 |
693,253 |
|
- |
|
| Truex Paul F |
President and CEO |
• • – |
2011-03-30 |
4 |
GD |
$0.00 |
$0 |
D/D |
693,253 |
91,122 |
|
- |
|
| Lowe Christopher P. |
VP of Administration and CBO |
• – – |
2011-02-11 |
4 |
S |
$0.00 |
$0 |
I/I |
(80,997) |
0 |
|
- |
|
| Hislop Colin |
Chief Medical Officer |
• – – |
2011-02-11 |
4 |
B |
$0.00 |
$0 |
D/D |
3,894 |
50,062 |
2.66 |
- |
|
| Thompson David E. |
Director |
– • – |
2011-01-03 |
4 |
OE |
$1.34 |
$16,067 |
I/I |
11,558 |
11,558 |
|
- |
|
| Isaly Samuel D |
10% Owner |
– – • |
2010-09-30 |
4 |
B |
$4.08 |
$81,192 |
I/I |
19,900 |
3,449,734 |
1.5 |
- |
|
| Isaly Samuel D |
10% Owner |
– – • |
2010-09-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,429,834 |
|
- |
|
| Lowe Christopher P. |
CFO & VP of Administration |
• – – |
2010-09-24 |
4 |
B |
$4.18 |
$20,900 |
D/D |
5,000 |
62,523 |
2.74 |
- |
|
| Odink Debra |
VP, Pharmaceutical R&D |
• – – |
2010-09-24 |
4 |
B |
$4.20 |
$4,200 |
D/D |
1,000 |
26,000 |
2.66 |
- |
|
| Leheny A. Rachel |
Director |
– • – |
2010-09-24 |
4 |
B |
$3.00 |
$750,000 |
I/I |
250,000 |
1,423,896 |
2.1 |
- |
|
221 Records found
|
|
Page 7 of 9 |
|
|
